Denise Oseguera is an Oncology nurse practitioner affiliated with University of California, Los Angeles. OpenAlex indexes 58 publications with 795 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Medical Plaza
#365,530,420,120
Los Angeles, CA 90095
Telephone
310-825-6301Registry record last updated 13 Jul 2010.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- NOVARTIS PHARMACEUTICALS CORPORATIONProgram year20232 payments
- Novartis Pharmaceuticals CorporationProgram year20224 payments
- NOVARTIS PHARMACEUTICALS CORPORATIONProgram year202111 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
80.7%Aromatase Inhibitor56.6%Anastrozole90%Letrozole10%Part D<11 patientsKinase inhibitor19.3%Ibrance41%Kisqali22%Everolimus20%Verzenio17%Part D<11 patients+ 1 more class in this area
Nervous system
7.5%gamma-Aminobutyric Acid A Receptor Positive Modulator4.2%Zolpidem Tartrate100%Part D<11 patientsOpioid Agonist3.3%Oxycodone-Acetaminophen100%Part D<11 patientsMetabolism & gastrointestinal
6.9%Serotonin-3 Receptor Antagonist6.9%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer
International Journal of Radiation Oncology*Biology*Physics
2023 - A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer
Cancer Research Communications
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Dennis Slamon, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
Robert Modlin, MD
University of California, Los Angeles
Zev Wainberg, MD
University of California, Los Angeles
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”